PDCD1 and neoplasm: Remodeling of tumors into inflamed ones by JX-594 led to a response to combined anti-PD-1 treatment in tumors, where single therapy, of either high-dose JX-594 or anti-PD-1 antibody, did not have significant tumor-reducing effects.